200 related articles for article (PubMed ID: 19996822)
1. The effect of intravitreal bevacizumab in the treatment of Coats disease in children.
Lin CJ; Hwang JF; Chen YT; Chen SN
Retina; 2010 Apr; 30(4):617-22. PubMed ID: 19996822
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab (avastin) therapy for idiopathic macular telangiectasia type II.
Kovach JL; Rosenfeld PJ
Retina; 2009 Jan; 29(1):27-32. PubMed ID: 18936721
[TBL] [Abstract][Full Text] [Related]
3. Findings in fluorescein angiography and optical coherence tomography after intravitreal bevacizumab in type 2 idiopathic macular telangiectasia.
Charbel Issa P; Holz FG; Scholl HP
Ophthalmology; 2007 Sep; 114(9):1736-42. PubMed ID: 17822979
[TBL] [Abstract][Full Text] [Related]
4. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
Ding X; Li J; Hu X; Yu S; Pan J; Tang S
Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab for Coats' disease with exudative retinal detachment and risk of vitreoretinal traction.
Ramasubramanian A; Shields CL
Br J Ophthalmol; 2012 Mar; 96(3):356-9. PubMed ID: 21653215
[TBL] [Abstract][Full Text] [Related]
6. Intravitreal bevacizumab (Avastin) for retinal angiomatous proliferation.
Meyerle CB; Freund KB; Iturralde D; Spaide RF; Sorenson JA; Slakter JS; Klancnik JM; Fisher YL; Cooney MJ; Yannuzzi LA
Retina; 2007; 27(4):451-7. PubMed ID: 17420697
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
Retina; 2007; 27(4):432-8. PubMed ID: 17420694
[TBL] [Abstract][Full Text] [Related]
8. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.
Haritoglou C; Kook D; Neubauer A; Wolf A; Priglinger S; Strauss R; Gandorfer A; Ulbig M; Kampik A
Retina; 2006; 26(9):999-1005. PubMed ID: 17151486
[TBL] [Abstract][Full Text] [Related]
9. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.
Kook D; Wolf A; Kreutzer T; Neubauer A; Strauss R; Ulbig M; Kampik A; Haritoglou C
Retina; 2008 Oct; 28(8):1053-60. PubMed ID: 18779710
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal bevacizumab for foveal detachment in idiopathic perifoveal telangiectasia.
Maia OO; Bonanomi MT; Takahashi WY; Nascimento VP; Takahashi BS
Am J Ophthalmol; 2007 Aug; 144(2):296-9. PubMed ID: 17659962
[TBL] [Abstract][Full Text] [Related]
11. Intravitreal bevacizumab in the management of subretinal fluid associated with choroidal osteoma.
Song JH; Bae JH; Rho MI; Lee SC
Retina; 2010 Jun; 30(6):945-51. PubMed ID: 20531145
[TBL] [Abstract][Full Text] [Related]
12. Management of Coats disease with bevacizumab in 2 patients.
Venkatesh P; Mandal S; Garg S
Can J Ophthalmol; 2008 Apr; 43(2):245-6. PubMed ID: 18347637
[No Abstract] [Full Text] [Related]
13. A combination of intravitreal bevacizumab injection with tunable argon yellow laser photocoagulation as a treatment for adult-onset Coats' disease.
Wang KY; Cheng CK
J Ocul Pharmacol Ther; 2011 Oct; 27(5):525-30. PubMed ID: 21951171
[TBL] [Abstract][Full Text] [Related]
14. Treatment of Coats' disease with intravitreal bevacizumab.
Ray R; Barañano DE; Hubbard GB
Br J Ophthalmol; 2013 Mar; 97(3):272-7. PubMed ID: 23269680
[TBL] [Abstract][Full Text] [Related]
15. Sequential combined treatment with intravitreal bevacizumab and photodynamic therapy for retinal angiomatous proliferation.
Viola F; Mapelli C; Villani E; Tresca Carducci F; Vezzola D; Ratiglia R
Eye (Lond); 2010 Aug; 24(8):1344-51. PubMed ID: 20339389
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy.
Avery RL; Pearlman J; Pieramici DJ; Rabena MD; Castellarin AA; Nasir MA; Giust MJ; Wendel R; Patel A
Ophthalmology; 2006 Oct; 113(10):1695.e1-15. PubMed ID: 17011951
[TBL] [Abstract][Full Text] [Related]
17. Eighteen-month follow-up of intravitreal bevacizumab in type 2 idiopathic macular telangiectasia.
Charbel Issa P; Finger RP; Holz FG; Scholl HP
Br J Ophthalmol; 2008 Jul; 92(7):941-5. PubMed ID: 18577646
[TBL] [Abstract][Full Text] [Related]
18. Elevated vascular endothelial growth factor level in Coats' disease and possible therapeutic role of bevacizumab.
He YG; Wang H; Zhao B; Lee J; Bahl D; McCluskey J
Graefes Arch Clin Exp Ophthalmol; 2010 Oct; 248(10):1519-21. PubMed ID: 20379736
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal bevacizumab (Avastin) associated with the regression of subretinal neovascularization in idiopathic juxtafoveolar retinal telangiectasis.
Jorge R; Costa RA; Calucci D; Scott IU
Graefes Arch Clin Exp Ophthalmol; 2007 Jul; 245(7):1045-8. PubMed ID: 17136357
[TBL] [Abstract][Full Text] [Related]
20. Resolution of severe macular edema in adult coats' disease with intravitreal triamcinolone and bevacizumab injection.
Jun JH; Kim YC; Kim KS
Korean J Ophthalmol; 2008 Sep; 22(3):190-3. PubMed ID: 18784449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
